{"transactions":[{"id":3862962,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":1750000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":158960},"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}},{"id":3862961,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":1750000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":158963},"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}},{"id":3862960,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 Preferred Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":342435,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31104},"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}},{"id":3862959,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":1333333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":155716},"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}},{"id":3862958,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":158960,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC."}],"balance_after":158960,"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}},{"id":3862957,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"purchase","acquired":true,"shares":266667,"price":15,"value":4000005.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC."}],"balance_after":612450,"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}},{"id":3862956,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":40531,"kind":"person","name":"Casdin Capital, LLC","position":1,"cik":"0001534261","reported_name":"Casdin Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40532,"kind":"person","name":"Casdin Partners Master Fund, L.P.","position":2,"cik":"0001534265","reported_name":"Casdin Partners Master Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40533,"kind":"person","name":"Casdin Partners GP, LLC","position":3,"cik":"0001534260","reported_name":"Casdin Partners GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36006,"kind":"person","name":"Casdin Eli","position":4,"cik":"0001534264","reported_name":"Casdin Eli","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164838,"kind":"organization","name":"Casdin Venture Opportunities Fund, L.P.","position":5,"cik":"0001730779","reported_name":"Casdin Venture Opportunities Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":164839,"kind":"organization","name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","position":6,"cik":"0001746899","reported_name":"CASDIN VENTURE OPPORTUNITIES FUND GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T20:12:01.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":345783,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC."}],"balance_after":345783,"source":{"system":"sec-edgar","filing":"0000899243-18-020457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730779/000089924318020457/doc4.xml","form_type":"4"}}]}